Cross Shore Discovery Fund | | | | | | | | | | | | |
Schedule of Investments (Unaudited) | | | | | | | | | | | | |
June 30, 2024 | | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | Next |
| | | | | | | | Initial | | | | Available |
| | % of | | | | | | Acquisition | | Redemption | | Redemption |
Portfolio Funds* | | Net Assets | | Cost(1) | | Fair Value | | Date | | Frequency(2) | | Date |
| | | | | | | | | | | | |
Long/Short Generalist: | | | | | | | | | | | | |
Atika Offshore Fund, Ltd., Class A, Series 1 | | 5.5% | | $ 677,447 | | $ 1,685,957 | | 1/2/2015 | | Quarterly | | 9/30/2024 |
| | | | | | | | | | | | |
EVR Offshore Partners Fund, Ltd., Class B, Series 02 | | 1.5% | | 437,521 | | 478,652 | | 12/31/2023 | | Quarterly | | 9/30/2024(3) |
| | | | | | | | | | | | |
Hawk Ridge Partners Offshore, Ltd., Class A, Initial Series | | 9.7% | | 1,600,000 | | 2,977,416 | | 2/1/2018 | | Quarterly | | 9/30/2024 |
| | | | | | | | | | | | |
Hill City Capital Offshore Fund Ltd., Class A, Series 14 | | 1.7% | | 438,600 | | 534,885 | | 11/1/2021 | | Quarterly | | 9/30/2024(3) |
| | | | | | | | | | | | |
TCIM Offshore Fund Ltd., Class A-33, Series 2019-12 | | 8.7% | | 1,756,890 | | 2,667,459 | | 12/1/2019 | | Monthly | | 7/31/2024 |
| | | | | | | | | | | | |
Wolf Hill Offshore Fund, Ltd., Class A-OS, Series 2020-08 | | 5.0% | | 1,300,000 | | 1,554,991 | | 7/1/2021 | | Quarterly | | 9/30/2024 |
| | | | | | | | | | | | |
Total Long/Short Generalist | | 32.1% | | 6,210,458 | | 9,899,360 | | | | | | |
| | | | | | | | | | | | |
Long/Short Sector: | | | | | | | | | | | | |
Energy | | | | | | | | | | | | |
Encompass Capital Fund Offshore Ltd., Class A, Series 1 | | 12.8% | | 1,803,039 | | 3,939,539 | | 1/1/2020 | | Quarterly | | 9/30/2024 |
| | | | | | | | | | | | |
Healthcare, Biotechnology | | | | | | | | | | | | |
Avoro Life Sciences Offshore Fund Ltd., Class A-1 | | 15.7% | | 1,069,545 | | 4,849,707 | | 5/1/2017 | | Quarterly | | 9/30/2024 |
Biomedical Offshore Value Fund, Ltd., Class I, Series 200199-1 | | 11.6% | | 2,100,000 | | 3,565,793 | | 1/1/2019 | | Quarterly | | 9/30/2024 |
| | | | | | | | | | | | |
Total Healthcare, Biotechnology | | 27.3% | | 3,169,545 | | 8,415,500 | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
Technology, Media and Telecommunications | | | | | | | | | | | | |
Atreides Foundation Fund, Ltd., Founders Class, Series F-2 | | 2.4% | | 396,380 | | 730,725 | | 5/15/2019 | | Quarterly | | 9/30/2024(3) |
| | | | | | | | | | | | |
Total Long/Short Sector | | 42.5% | | 5,368,964 | | 13,085,764 | | | | | | |
| | | | | | | | | | | | |
Total Investments In Portfolio Funds | | 74.6% | | $ 11,579,422 | | $ 22,985,124 | | | | | | |
| | | | | | | | | | | | |
Open-End Mutual Funds | | | | | | | | Shares | | | | |
Large Growth | | | | | | | | | | | | |
Fidelity Blue Chip Growth Fund | | 4.5% | | 1,250,000 | | 1,374,920 | | 6,250 | | | | |
| | | | | | | | | | | | |
| | % of | | | | | | | | | | |
Money Market Funds | | Net Assets | | Cost | | Fair Value | | Shares | | | | |
| | | | | | | | | | | | |
Federated Hermes Institutional Prime Obligations Fund, | | | | | | | | | | | | |
Institutional Class, 5.34%(4) | | 15.4% | | $ 4,740,071 | | $ 4,738,490 | | 4,737,543 | | | | |
| | | | | | | | | | | | |
Total Investments | | 94.5% | | $ 17,569,493 | | $ 29,098,534 | | | | | | |
| | | | | | | | | | | | |
Other Assets in Excess of Liabilities | | 5.5% | | | | $ 1,693,567 | | | | | | |
| | | | | | | | | | | | |
Net Assets | | 100.0% | | | | $ 30,792,101 | | | | | | |
| | | | | | | | | | | | |
* Non-income producing security. | | | | | | | | | | | | |
(1) There were no unfunded capital commitments as of June 30, 2024. | | | | | | | | | | | | |
(2) Certain redemptions may be subject to various restrictions and limitations such as redemption penalties on investments liquidated within a certain period subsequent to investment (e.g., a soft or hard lock-up), investor-level gates and/or Portfolio Fund-level gates. Redemption notice periods range from 30 to 120 days. |
(3) Subject to 25% investor level quarterly gate. | | | | | | | | | | | | |
(4) Rate disclosed is the seven day effective yield as of June 30, 2024. | | | | | | | | | | | | |